Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
GAITHERSBURG, Md., Feb. 05, 2018 -- OpGen, Inc. (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’s stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market. In addition, the Company has been informed that it is in compliance with all applicable listing standards of The Nasdaq Capital Market and that therefore its hearing before the Nasdaq Hearings Panel, which had been scheduled for February 8th, has been cancelled.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen, and Acuitas are registered trademarks of OpGen, Inc.
OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
[email protected]
[email protected]
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]
